UpdatesPlus - Immunology

Chronic hand eczema (CHE) is a well-recognized inflammatory disorder.To evaluate the efficacy and safety of 1.5% ruxolitinib cream in adults with moderate to severe CHE.This phase 2 study enrolled adults with CHE from North America and Europe, an Investigator's Global Assessment (IGA)-CHE score of 3/4, ≥1 prior CHE therapy, and no current or recent history (≤5 y) of atopic dermatitis. Patients were randomized 1:1 to twice-daily 1.5% ruxolitinib cream or vehicle cream for 16 weeks.Among 186 randomized patients, most who applied ruxolitinib cream achieved a score of 0 (clear) or 1 (almost clear) on the IGA-CHE scale with a 2-grade improvement from baseline at Week 16 (53.2% vs 10.9% [vehicle]; PRelatively small sample size.Ruxolitinib cream represents an effective treatment option for nonatopic CHE subtypes that are not controlled with standard therapies.